IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-017-2570-1
Abstract: Management of low-grade gliomas (LGG) is based on clinical and radiologic features, including the Pignatti prognostic scoring system, which classifies patients as low- or high-risk. To determine whether molecular data can offer advantages over these… read more here.
Keywords: risk; mutations 19q; idh mutations; grade gliomas ... See more keywords
The clinical use of IDH1 and IDH2 mutations in gliomas
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Molecular Diagnostics"
DOI: 10.1080/14737159.2018.1548935
Abstract: ABSTRACT Introduction: Mutations in the genes isocitrate dehydrogenase (IDH) 1 and 2 have been reported in a limited number of tumors. In gliomas, IDH mutations are primarily detected in WHO grade II–III tumors and represent… read more here.
Keywords: use; idh mutations; idh; role ... See more keywords
Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Sign Up to like & getrecommendations! Published in 2018 at "Neurosurgery"
DOI: 10.1093/neuros/nyy338
Abstract: BACKGROUND IDH mutation is an important prognostic factor of diffuse astrocytomas. Although the majority of IDH mutations could be identified by immunohistochemical (IHC) stain for R132H-mutant IDH1, DNA sequencing would be required for IHC negative… read more here.
Keywords: diffuse; idh mutations; bcat1; r132h ... See more keywords
Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.2028
Abstract: 2028 Background: According to the 2016 WHO classification of Central Nervous System tumors, the assessment of exon 4 mutations in IDH1 or IDH2 genes is an essential step in the characterization of gliomas. The R132H… read more here.
Keywords: canonical mutations; canonical idh1; non canonical; idh mutations ... See more keywords
Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
Sign Up to like & getrecommendations! Published in 2022 at "Neurosurgical focus"
DOI: 10.3171/2021.11.focus21604
Abstract: Immunotherapy has emerged as a promising approach for treating aggressive solid tumors, even within the CNS. Mutation in the metabolic gene isocitrate dehydrogenase 1 (IDH1) represents not only a major glioma defining biomarker but also… read more here.
Keywords: implications idh; mutations immunotherapeutic; malignant glioma; idh mutations ... See more keywords
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14051125
Abstract: Simple Summary Mutations of isocitrate dehydrogenase (IDH) genes are the distinctive genetic feature of lower-grade gliomas (LGGs). Tumor-associated IDH1/2 mutations result in a loss of normal enzymatic function and the abnormal production of 2-hydroxyglutarate (2-HG),… read more here.
Keywords: oncology; grade gliomas; idh mutations; idh ... See more keywords